NAVF Pharma Cannabis Fund

Pharmaceutical investment isn’t a topic most people discuss over coffee, yet it shapes the medicines that reach shelves—and sometimes the companies behind them. NAVF Pharma Cannabis Fund operates in this quiet corner of finance, focusing on the therapeutic potential of cannabis-related assets. The fund’s work reflects a growing intersection between biotech innovation and regulatory landscapes, where science meets capital.

Their office sits at 30 Wall St, 8th floor, New York, NY 10005, a building that hums with the energy of Lower Manhattan. This stretch of Wall Street isn’t just about skyscrapers; it’s where decisions ripple through industries, including healthcare. For those tracking the evolution of pharmaceutical funding, this address anchors a conversation that extends far beyond the Financial District.

Questions about the fund’s portfolio or investment criteria can be directed to (212) 634-4300. The number connects callers to a team that navigates the complexities of drug development pipelines and market trends. It’s a niche dialogue, but one that influences which treatments gain momentum—and which remain on the drawing board.

Directions to the office are available on the map, though the real journey lies in understanding how capital fuels medical progress. NAVF Pharma Cannabis Fund’s role is part of that larger story, unfolding one investment at a time.